Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OliPass Corp.

www.olipass.com

Latest From OliPass Corp.

Incentives, Novel Tech Seen Driving Multiple Korean IPOs In 2018

Despite an expected absence of large floats like that of Celltrion Healthcare last year, IPOs by biotech and pharma firms in South Korea are poised to rise in 2018 amid an improved stock listing environment and progress in novel drug development.

Commercial Financing

Interview: OliPass An Oligonucleotide Outsider With Big Ambitions

South Korean bioventure OliPass tells Scrip how it intends to grab a leading position in the global antisense oligonucleotide drug sector using in-house developed technology that it says can both sharply lower prices and increase safety in the field, where it is initially focusing on novel pain therapies.

South Korea Commercial

Deals Shaping The Medical Industry, December 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced October-November 2014.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • OliPass Corp.
  • Senior Management
  • Shin Chung, PhD, CEO
    Jongho Park, CFO
  • Contact Info
  • OliPass Corp.
    Phone: 31-888-9562
    145 Gwanggyo, Bldg. A, AICT
    4th Fl.
    Suwon-si, Gyeonggi-do,
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register